South Korean biotechnology company founded in 2018 that develops retroviral and lentiviral vector platforms and services for cell and gene therapy development
South Korean biotechnology company founded in 2018 that develops retroviral and lentiviral vector platforms and services for cell and gene therapy development. Its RetroNext and LentiNext platforms use non-integrating, safe-integration, and high-efficiency technologies, including integrase control, to improve vector safety and gene delivery. It also offers customized vector design and vector packaging services.